 |
 Video: What is a Stock Split?
|
|
|
| Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. According to our Viking Therapeutics stock split history records, Viking Therapeutics has had 0 splits. | |
|
Viking Therapeutics (VKTX) has 0 splits in our Viking Therapeutics stock split history database.
Looking at the Viking Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Viking Therapeutics shares, starting with a $10,000 purchase of VKTX, presented on a split-history-adjusted basis factoring in the complete Viking Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2015 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$8.96 |
|
| End price/share: |
$76.97 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
759.04% |
|
| Average Annual Total Return: |
26.93% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$85,914.15 |
|
| Years: |
9.02 |
|
|
|
|
|
